BridgeBio to Present Key Findings on Genetic Diseases
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a pioneering biopharmaceutical company, is set to showcase ten significant moderated digital posters at the American Heart Association (AHA) Scientific Sessions 2025. This event will occur from November 7 to 10 and will be based in New Orleans.
Focus on Acoramidis and ATTR-CM
The focal point of BridgeBio's presentations will include pivotal research around Acoramidis, specifically its effects on patients afflicted with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM). These findings stem from the extensive ATTRibute-CM study, which aims to shed light on this debilitating condition.
Acoramidis and Mortality Rates
One of the highlights will be a presentation led by Marianna Fontana, M.D., from University College London. This session will discuss how Acoramidis impacts all-cause mortality in patients with this specific variant of ATTR-CM, taking place on Saturday, November 8, at 3:15 PM CT.
Cardiovascular Hospitalizations
Furthermore, Prem Soman, M.D., Ph.D., from the University of Pittsburgh School of Medicine, will present findings showing how Acoramidis can reduce all-cause mortality and the likelihood of first cardiovascular hospitalization among patients with variant transthyretin amyloid cardiomyopathy. This presentation will occur earlier that same day at 9:15 AM CT.
Broader Implications of Acoramidis Research
The research expands as Lily Stern, M.D., from Cedars-Sinai Heart Institute, presents on the enduring effects of Acoramidis, emphasizing its ability to reduce mortality and cardiovascular-related hospitalizations through a period of 42 months among all patient subgroups. This comprehensive analysis will also take place on Saturday, November 8.
Impact on Diagnostic Parameters
Moreover, Mathew Maurer, M.D., from Columbia University Irving Medical Center, will delve into how Acoramidis lowers NT-proBNP, highlighting its efficacy compared to placebo. This significant insight into cardiomyopathy and its direct outcomes will be shared on the same day at 9:15 AM CT.
Addressing Treatment Disparities
Noteworthy discussions will also focus on demographic disparities in treatment efficacy and clinical outcomes across the United States. Nicole Cyrille-Superville, M.D., from Atrium Health Sanger Heart & Vascular Institute, will address these disparities on November 8 at 12:15 PM CT.
Geographic Variability in Disease Prevalence
Sandesh Dev, M.D., from Southern Arizona VA Health Care System, will provide studies examining the geographic discrepancies in the prevalence of transthyretin amyloid cardiomyopathy, continuing the conversation on November 8.
Research Outcomes Shape Future Therapies
Nitasha Sarswat, M.D., from UChicago Medicine, will share findings linking serum transthyretin levels at day 28 with cardiovascular outcomes on Sunday, November 9, at 3:15 PM CT. This research holds potential implications for refining patient management and treatment approaches.
Clinical Outcomes and Quality of Life
Richard Cheng, M.D., also presents on November 9, emphasizing how Acoramidis improves clinical outcomes, function, and quality of life for patients, regardless of their atrial fibrillation status at baseline.
Future Directions for BridgeBio
Looking ahead, Ronald Witteles, M.D., from Stanford University School of Medicine, will elucidate how Acoramidis can significantly reduce both all-cause mortality and cardiovascular-related hospitalization risks in early-stage heart failure patients, a promising aspect of their research initiative.
Healthcare Utilization Analysis
Finally, Nicole Bart, M.D., Ph.D., from St Vincent's Hospital Sydney, will present a retrospective analysis regarding the healthcare resource utilization, costs, and patient mortality related to Vutrisiran, concluding the poster presentations on November 10.
About BridgeBio and Acoramidis
BridgeBio is dedicated to discovering transformative medicines that target genetic diseases. Their flagship product, Acoramidis, is a transthyretin stabilizer specifically designed to provide essential treatment for adults suffering from the cardiomyopathy associated with both wild-type and variant forms of transthyretin-mediated amyloidosis. The company’s commitment towards addressing these genetic conditions positions it as a visionary leader in biopharmaceutical advancements.
Frequently Asked Questions
What is the significance of the AHA Scientific Sessions 2025?
The AHA Scientific Sessions is a prestigious event where researchers share groundbreaking findings in cardiovascular health, providing a platform for innovation and collaboration.
What is the role of Acoramidis in treating ATTR-CM?
Acoramidis is designed to stabilize transthyretin, aiming to reduce cardiovascular death and related hospitalizations for patients with ATTR-CM.
Who will be presenting at the AHA event?
Several prominent researchers, including Dr. Marianna Fontana and Dr. Prem Soman, among others, will present new findings related to Acoramidis and its effects.
What outcomes are being evaluated in the presentations?
Key outcomes include mortality rates, hospitalization risk, demographic disparities, and healthcare resource utilization related to treatment.
How does BridgeBio contribute to genetic disease treatment?
BridgeBio focuses on developing innovative therapies that specifically target genetic anomalies, aiming for rapid delivery and impactful patient outcomes.
